Biology subjects

Davidson, K.

Publications and source records attributed to Davidson, K..

4 recordsLinked to original sources

bioRxiv2026

Loss of Sun2 ablates nuclear mechanosensing-driven extracellular matrix production and mitigates lung fibrosis

Fibrosis and pathological stiffening of tissue are driven by mechanical and biochemical signaling pathways. Here, we find that Sun2, an integral inner nuclear membrane component of Linker of Nucleoskeleton and Cytoskeleton (LINC) complexes, is up-regulated in the lung of patients suffering from fibrotic conditions and in fibroblasts during an injury-induced mouse model of lung fibrosis. Sun2 protein levels also increase in primary lung fibroblasts in a substrate stiffness-dependent manner. Sun2-/- primary lung fibroblasts respond to TGF{beta}, become contractile, and express a key marker of extracellular matrix-producing fibroblasts, Cthrc1. Consistent with this, Sun2 is dispensable for myofibroblast formation and repairing the alveolar barrier after bleomycin injury. Remarkably, however, fibrosis does not develop in bleomycin-treated Sun2-/- mouse lungs. This is explained by the requirement for Sun2 to up-regulate genes encoding extracellular matrix proteins. We therefore suggest that Sun2-containing LINC complexes contribute to a mechanical coincidence detection mechanism that acts in concert with canonical TGF{beta} signaling necessary for pathologic extracellular matrix protein production, representing a nuclear mechanosensing node for intervention in fibrotic diseases of the lung.

cell biology↗

bioRxiv2026

SUN2 mediates epigenetic remodeling to drive mechanotransduction during skin fibrosis

Fibrosis involves sustained changes in fibroblast gene expression, leading to excessive extracellular matrix (ECM) deposition and progressive tissue stiffening. Although matrix stiffness is a potent regulator of cell fate and transcription, it is not clear how nuclear mechanosensing contributes to fibrosis. Here, we define a central role for SUN2, a component of linker of nucleoskeleton and cytoskeleton (LINC) complexes, as a mediator of stiffness-dependent nuclear and chromatin responses during skin fibrosis. SUN2 transcripts are upregulated in dermal fibroblasts of patients with systemic sclerosis and Sun2 protein is elevated in fibrotic mouse skin. Nuclear size, A-type lamins and Sun2 are elevated in dermal fibroblasts plated on stiff substrates. Loss of Sun2 protects against bleomycin-induced skin fibrosis in vivo and abolishes stiffness-induced changes in nuclear size and fibrotic gene expression in vitro. Mechanistically, we identify three Sun2-dependent mechanosensitive chromatin states and show that mechanical induction of the histone methyltransferase Ezh2 requires Sun2. These findings define SUN2 as a nuclear mechanosensor that couples matrix stiffness to chromatin regulation and transcriptional programs that drive fibrosis, identifying it as a potential therapeutic target pathway in fibrotic disease.

cell biology↗

bioRxiv2024

β-Amyloid impairs Proteasome structure and function. Proteasome activation mitigates amyloid induced toxicity and cognitive deficits

BackgroundImpaired proteasome activity is a robust and reproducible feature in Alzheimers disease (AD) patients and animal models. Although amyloid beta (A{beta}) may inhibit proteasomes, it is unclear if this reflects direct structural interference or indirect toxicity. The proteasome controls a myriad of critical neuronal processes with its disruption potentially driving downstream AD pathology. MethodsWe examined the direct impact of distinct A{beta} forms on proteasome structure, dynamics, and function by evaluating enzyme activity and morphology by atomic force microscopy (AFM) and native-gel electrophoresis. To prevent A{beta}-induced impairments in vitro and in AD animal models, we used allosteric proteasome activating peptidomimetics. We characterized their interactions with proteasome by AI enhanced in silico docking. ResultsToxic soluble A{beta}42 oligomers selectively inhibit 20S and 26S proteasome activity, while monomeric and fibrillar forms and A{beta}40 show minimal inhibitory effects. Morphometric analysis of AFM images suggests A{beta}42 oligomers bind laterally to the 20S proteasomes, and impair proteasome dynamics by disabling gate opening, critical for catalytic activity. Oligomer-decorated proteasomes are locked in catalytically inert cycling between closed and intermediate gate conformations. Oligomeric A{beta}42 also induces disassembly of the 26S complex, increasing content of free 20S cores. Importantly, we show proteasome dysfunction induced by oligomeric A{beta}42 is both preventable and reversible by employing an allosteric proteasome activator TAT-DEN, promoting gate opening and restoring enzymatic activity with the full-cycle of conformational transitions in oligomers-treated proteasomes. In cellular and animal models, restoring proteasome function via TAT-DEN mitigated A{beta}-induced cell death, spatial learning/memory deficits, and survival impairments, even under conditions of pre-established A{beta} deficits. ConclusionsOligomeric A{beta}42 decorates the lateral sides of the 20S proteasome restricting cycling between conformations and blocking gate opening. It also reduces the pool of 26S proteasomes necessary for the ubiquitin-dependent protein degradation. We demonstrate proteasome dysfunction can be prevented and reversed by proteasome agonist that lowers 20S affinity to oligomers and promotes allosteric gate opening. We show that proteasome activation with TAT-DEN prevents cognitive deficits in AD animal models. This suggests proteasome dysfunction is a key downstream target in AD pathology and supports proteasome activation as a therapeutic strategy to restore neuronal function in AD.

molecular biology↗

bioRxiv2021

Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.

An early event in lung oncogenesis is loss of the tumour suppressor gene LIMD1 (LIM domains containing 1); this encodes a scaffold protein, which suppresses tumourigenesis via a number of different mechanisms. Approximately 45% of non-small cell lung cancers (NSCLC) are deficient in LIMD11, yet this subtype of NSCLC has been overlooked in preclinical and clinical investigations. Defining therapeutic targets in these LIMD1 loss-of-function patients is difficult due to a lack of druggable targets, thus alternative approaches are required. To this end, we performed the first drug repurposing screen to identify compounds that confer synthetic lethality with LIMD1 loss in NSCLC cells. PF-477736 was shown to selectively target LIMD1 deficient cells in vitro through inhibition of multiple kinases, inducing cell death via apoptosis. Furthermore, PF-477736 was effective in treating LIMD1-/- tumors in subcutaneous xenograft models, with no significant effect in LIMD1+/+ cells. We have identified a novel drug tool with significant preclinical characterization that serves as an excellent candidate to explore and define LIMD1-deficient cancers as a new therapeutic subgroup of critical unmet need. Significance StatementHere we provide the first proof-of-concept data validating the scope for development of a targeted therapy against the non-small cell lung cancers (NSCLC) subtypes deficient in expression of the LIMD1 tumor suppressor gene. Approximately 45% of NSCLC are deficient in LIMD11 representing at least 1.2 million lung cancer patients worldwide; yet this subtype has been ignored in preclinical and clinical investigations with no targeted therapies available. This seminal study applied synthetic lethality drug screening to target the loss/reduction of LIMD1 in lung cancer and normal cell lines, identifying and validating the multi-kinase inhibitor PF-477736 as a selectively cytotoxic compound towards LIMD1 deficient cells. This study provides rationale for further investigation into targeting LIMD1 loss in lung cancer, thereby addressing a critical unmet need for therapeutic approached to targeting LIMD1-deficent cancer subtypes.

cancer biology↗